Introducing a new cryoprecipitated coagulopathy treatment: INTERCEPT® Fibrinogen Complex

Presented at the Cerus Workshop at SABM Annual Meeting September 2021:
Clinical Need for, and Experience with, The New Pathogen Reduced Cryoprecipitated Fibrinogen Complex: INTERCEPT® Fibrinogen Complex

This presentation offers a brief product description of pathogen reduced cryoprecipitated fibrinogen complex, better known as INTERCEPT® Fibrinogen Complex, the first cryoprecipitated source of clotting factors ready for patients when minutes matter

Presented by:
Nadia Keltner, MSc, PhD
Associate Director, Therapeutics Market Development
Cerus Corporation

Dr. Keltner is the Associate Director of the Therapeutics Market Development team for Cerus Corporation. Prior to the past 5 years at Cerus Corporation, she worked in physician and patient market research. She holds a BA from the University of California, Berkeley, an MSc from Columbia College of Physicians and Surgeons, and a PhD from Boston University School of Medicine.


Watch the Replay
Runtime: 4 min